Navigation Links
CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
Date:7/22/2013

INDIANAPOLIS, July 22, 2013 /PRNewswire/ -- CRO Solutions, Inc. announced the launch of VxP Pharma, Inc.- a wholly owned subsidiary of CRO Solutions, Inc. VxP Pharma is comprised of the combined services of the independently owned and operated "niche" CROs of parent company - CRO Solutions, Inc. VxP Pharma will offer pharmaceutical development services, as well as technical support, for the development and production of pharmaceuticals, diagnostics, and drug/device combination products from Discovery through Phase IIb.

The majority of VxP Pharma's Labs are located in the United States, although VxP also has facilities in Europe and Asia. All VxP sites have been fully audited by CRO Solutions/VxP Pharma, as well as by global pharmaceutical and biotechnology clients. Most sites have also been audited by the US FDA as well as other international regulatory agencies.

VxP Pharma CEO - Raymond E Peck says "Pharmaceutical and biotech research scientists throughout the industry tell us that they prefer to work with smaller, focused, Contract Research Organizations (CROs), rather than with the huge multinational 'one-size-fits-all' CROs. For these people, VxP Pharma is a perfect fit because we offer a single point of contact, as well as the confidence that, if you work with VxP, you are working with a state-of-the-art lab that has been subject to a complete audit, including, in most cases, an audit by the US FDA. Because VxP consists of smaller, independently owned and operated facilities who focus on only one area of drug development, our drug development clients get all the advantages of working directly with a specialist "niche" CRO, including being able to work with some of the best subject matter experts in the industry."

VxP Pharma will operate as a full service CRO offering drug development services from Discovery through Phase llb. VxP is headquartered in Indianapolis, Indiana. To find out more, please visit: www.vxppharma.com or call at 317-759-2299.

Press Release Contact Information:
Lisa Fay
Director of Client Development
VxP Pharma Services, Inc.
317-759-2299
Lisa.Fay@VxPPharma.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.


'/>"/>
SOURCE VxP Pharma Services, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MEDIFIRST SOLUTIONS, INC. To Exhibit At The Orlando International Beauty Show
2. Medifirst Solutions, Inc. Announces Update To Shareholders
3. Medifirst Solutions, Inc. Announces New Healthcare And Wellness Division
4. Comprehensive Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
5. Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
6. inVentiv Health Forms Strategic Alliance With Bell Medical Solutions, One Of Japans Top Clinical Research Organizations
7. Managed Health Care Associates, Inc. (MHA) Announced Erik Halstrom, Vice President of MHA Specialty Pharmacy Solutions, Will Serve on the National Association of Specialty Pharmacy (NASP) Board of Directors
8. Qualyst Transporter Solutions, LLC Announces New Alliance with GenoMembrane
9. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
10. Catalent Pharma Solutions, Inc. Announces Increase In Tender Cap For Its Cash Tender Offer For Its 9-1/2%/10-1/4% Senior PIK-Election Notes Due 2015
11. Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):